Ascendis Pharma (ASND) Tops Q1 EPS by 31c

Ascendis Pharma (NASDAQ: ASND) reported Q1 EPS of (EUR0.06), EUR0.31 better than the analyst estimate of (EUR0.37). Revenue for the quarter came in at EUR2.1 million versus the consensus estimate of EUR2.24 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• Penguin Solutions (PENG) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY26 EPS Guidance
• RBC Capital Starts Shawbrook Group plc (SHAW:LN) at Outperform